Drugs are made for the majority but not everyone is the majority.
The CPNDS is finding drug safety solutions by seeking explanations for why one patient experiences an adverse drug reaction and another patient who takes the same drug does not. The CPNDS is exploring genetic variation as a key factor in the occurrence of serious adverse drug reactions. The presence of specific genetic variations can predict in whom serious adverse drug reactions are likely to occur before a drug is given. In this way, therapy can be modified to prevent serious adverse drug reactions from occurring.